Objective. To review the antidepressant efficacy of S-Adenosyl-L-Methionine (SAMe) both in
monotherapy and/or in augmentation with antidepressants to better understand its potential …

Abstract As many as 29% to 46% of patients with major depressive disorder (MDD) show
only partial or no response to an adequate course of an antidepressant. The current practice …

Background Major depressive disorder (MDD) is a recurrent illness with high rates of
chronicity, treatment-resistance, and significant economic impact. S-Adenosylmethionine …

Preclinical Research S‐adenosyl methionine (SAM) is a major methyl donor and as such
exerts its influence on CNS function through methylation reactions, such as methylation of …

Objective: A systematic review on S-adenosylmethionine (SAMe) for treatment of
neuropsychiatric conditions and comorbid medical conditions. Data Sources: Searches were …

Despite the increasingly large array of antidepressants available to treat major depressive
disorder, patients continue to experience relatively modest response and remission rates. In …

Introduction‐S‐adenosyl‐l‐methionine (SAMe) is a naturally‐occurring substance which is a
major source of methyl groups in the brain. Material and methods‐We conducted a meta …

S‐adenosyl‐l‐methionine (SAMe), a naturally occurring brain metabolite, has previously
been found to be effective and tolerated well in parenteral form as a treatment of major …

Summary S-Adenosylmethionine (SAMe; ademetionine) is a naturally occurring compound
that is found in virtually all living organisms. It serves as a major source of methyl groups in …

Major depression remains difficult to treat, despite the wide array of registered
antidepressants available. In recent years there has been a surge in the popularity of natural …